EVH

Evolent Health, Inc. (EVH) SWOT Analysis Analysis (2026)

Invetso Score: 3.4/10 — Weak · Last Updated: 2026-08-01

Strengths

A current ratio of 1.24 indicates near-term liquidity is adequate, but peers with stronger balance sheets can fund operations and working capital more flexibly.

Net debt to EBITDA of -2.70 suggests EBITDA is insufficient to cover leverage cleanly, yet the metric is less informative than for peers with positive earnings.

Cash conversion cycle of 70.4 days shows working-capital discipline is present, although it remains longer than best-in-class peers that recycle cash faster.

Return on invested capital of -1.9% is weak, but the business still preserves some operating resilience relative to peers with deeper capital destruction.

Weaknesses

Return on invested capital of -1.9% signals value destruction, leaving EVH structurally behind peers that consistently earn returns above capital costs.

Debt to equity of 2.53 indicates elevated financial leverage, which constrains strategic flexibility versus less levered peers in the same sector.

A cash conversion cycle of 70.4 days ties up capital for longer than stronger peers, reducing reinvestment capacity and margin of safety.

Liquidity is only moderate at 1.24 on both current and quick ratios, leaving less cushion than peers with stronger short-term coverage.

Opportunities

Improving invested-capital returns would have outsized impact because peers with positive ROIC can compound faster and widen valuation gaps over time.

Reducing working-capital days could release cash for deleveraging or reinvestment, narrowing the gap with peers that convert earnings more efficiently.

If leverage is reduced, EVH could improve financial flexibility relative to peers, supporting steadier execution through cyclical or reimbursement pressure.

Operational simplification could lift capital efficiency, helping EVH close the profitability gap with peers that already operate with leaner asset bases.

Threats

Persistently negative ROIC threatens long-term competitiveness because peers with positive returns can reinvest more aggressively and compound market share.

Higher leverage increases sensitivity to earnings volatility, making EVH more vulnerable than peers with cleaner balance sheets and lower refinancing risk.

A long cash conversion cycle can pressure liquidity during slower collections, while peers with faster cycles retain more operating flexibility.

If capital efficiency does not improve, peers with stronger economics can outspend EVH on growth, technology, and service capabilities.

Overall Score

EVH’s structural positioning versus peers is weak overall because negative capital returns and elevated leverage outweigh modest liquidity and working-capital stability.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Evolent Health, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →